Edison Oncology Holding Corp
Edison Oncology is a clinical-stage biopharmaceutical company developing biomarker-driven, targeted therapies for cancer. They focus on identifying and developing promising drug candidates for patients with tumors most likely to respond. Combining internal development and strategic partnerships, they aim to improve cancer patient outcomes and create substantial value.
Registre Officiel
Analyse Qualité IA
Détails du Score de Confiance
Liens Rapides
Points forts du site
🌟 Entreprises similaires de confiance
Kalaris Therapeutics, Inc.
Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. They focus on innovative retinal treatments, including TH103, a potential best-in-class anti-VEGF agent for neovascular AMD. Kalaris aims to ease patient burden and improve outcomes in retinal disease management.
Vor Biopharma Inc.
Vor Bio is a biopharmaceutical company focused on reinventing autoimmune disease treatment by targeting its root causes. Their lead program, telitacicept, is a potential first-in-class dual BAFF/APRIL inhibitor designed to silence survival signals of harmful B cells, aiming to halt autoantibody production. Vor Bio is committed to advancing transformative therapies that move beyond symptom control. They aspire to become a global leader in targeted autoimmune disease therapeutics.
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer. They focus on in-licensing innovative drug candidates that have undergone clinical testing. Puma Biotechnology aims to improve cancer treatment through innovative drug development.